In comparison, Q LFLC was higher than the Q Alb-dependent upper reference value in 36.1% of patients with AI-CNS-D, in 40.0% of patients with CIS, in 7.7% of patients with CIDP, in 7.7% of patients with GBS, in 37.9% of patients with CNS-I, in 42.9% of patients with CNS tumor, in 21.1% patients with P-CNS-I, in 20.0% of patients with ME, in 7.1% of patients with PP-PNP, and in 0.9% of patients with NIND. Here, ALB is linked to in situ carcinoma.